Unmet Needs and Looking Ahead in Essential Thrombocythemia
Unmet needs and current areas that are being studied in in essential thrombocythemia.
Read More
The Treatment Spectrum in Essential Thrombocythemia
Pankit Vachhani, MD, highlights treatment considerations in low- to high-risk essential thrombocythemia and patients resistant or intolerant to hydroxyurea.
Read More
Essential Thrombocythemia: An Overview
Expert discusses risk-stratification models, prognosis, and the management of complications in essential thrombocythemia.
Read More
Ongoing Unmet Needs and New Approaches in Myelofibrosis
Key opinion leaders discuss the current unmet needs in myelofibrosis and ongoing approaches to look forward to in hopefully overcoming these challenges.
Read More
A Review of Pacritinib and PACIFICA Data
Srdan Verstovsek, MD, PhD, briefly reviews the role of pacritinib in patients with myelofibrosis as well as the PACIFICA study.
Read More
The Role of Transplant in Myelofibrosis
Experts discuss the role of transplant and evaluating options in patients with myelofibrosis.
Read More
COMFORT Data and Ruxolitinib in Myelofibrosis
A review of data from the COMFORT trials and the management and real-world use of ruxolitinib in patients with myelofibrosis, also touching on its use during the coronavirus pandemic.
Read More
A Look at Fedratinib and the JAKARTA Trials
Srdan Verstovsek, MD, PhD, reviews data from the JAKARTA and JAKARTA2 clinical trials as well as his approach to using fedratinib in his own clinical practice.
Read More
Risk, Prognosis, and Nontransplant Options in Primary Myelofibrosis
Ruben A. Mesa, MD, and Srdan Verstovsek, MD, PhD, provide insight on the disease burden and prognostic scoring of primary myelofibrosis, as well as options for nontransplant candidates.
Read More
Goals in Treating Low-Risk Primary Myelofibrosis
Srdan Verstovsek, MD, PhD, shares how he assesses and typically starts treatment in patients with low-risk primary myelofibrosis, looking specifically at whether patients are symptomatic or asymptomatic.
Read More
Emerging Therapeutic Options in Polycythemia Vera
What to look forward to in the polycythemia vera space, including new clinical trials.
Read More
Real-World Use of Ruxolitinib in Polycythemia Vera
Experts give real-world insight in using ruxolitinib in patients with polycythemia vera.
Read More
Polycythemia Vera: An Update on Clinical Trials
Experts discuss clinical trial updates in polycythemia vera, including data from RESPONSE, RESPONSE-2, an international observational study of ruxolitinib, and REVEAL.
Read More
PV Progression and Guideline-Directed Management
Ruben A. Mesa, MD, highlights signs of disease progression and the utilization of guideline recommendations in the occurrence of a thrombotic event when treating polycythemia vera.
Read More
Therapeutic Considerations in Polycythemia Vera
Key opinion leaders discuss treatment goals, considerations, and guideline recommendations for patients with low- or high-risk polycythemia vera.
Read More
Diagnosis and Evaluation in Polycythemia Vera
Evaluating treatment, diagnostic criteria, and risk-assessment tools in polycythemia vera.
Read More
An Overview of Myeloproliferative Neoplasms
Srdan Verstovsek, MD, PhD, provides an overview of the similarities and differences between myeloproliferative neoplasms, including polycythemia vera, myelofibrosis, and essential thrombocythemia.
Read More
Individualizing Treatment Approaches in MPN
Experts provide insight on therapeutic approaches of myeloproliferative neoplasms, highlighting clinical trial data and disease characteristics of polycythemia vera, primary myelofibrosis, and essential thrombocythemia.
Read More